TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04135937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Smoking cessation pharmacotherapy prescribed in accordance with package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Smoking cessation pharmacotherapy prescribed in accordance with package insert.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Text Messaging
Description: Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
Study: NCT03428243

Intervention type: DEVICE
Intervention: truSculpt
Description: Device comparison of Circumference measurement at Baseline vs 18 months post treatment
Study: NCT03205319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-learning
Description: The e-learning for patients is a user friendly, audiovisual based, online-accessible program, designed especially for this study. The e-learning will contain information on dyspepsia and advice on lifestyle interventions
Study: NCT03991234

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Intervention
Description: Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction to build skill on letter-sound associations, decoding, sight words, \& contextualized reading.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Math Intervention
Description: Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge \& counting strategies to build arithmetic skill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Intervention
Description: Coordinated intervention provides 15 weeks (30-minute sessions per week) of explicit instruction addressing the similar skills as in the reading intervention arm \& similar objectives as the math intervention arm.
Study: NCT00256178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and simvastatin
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and simvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Study: NCT01545817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib followed by everolimus
Description: All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
Study: NCT00256178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Study: NCT02291237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablet (s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablet (s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match eleclazine administered orally once daily
Study: NCT02026401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Study: NCT03252522

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
Description: 60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
Description: 60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
Study: NCT02383667

Intervention type: DEVICE
Intervention: Electrocardiogram holter
Study: NCT02327429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Chinese menu plan for type 2 diabetes
Description: The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
Study: NCT02492906

Intervention type: OTHER
Intervention: Osteoarthrosis
Description: Primary severe knee osteoarthrosis and chronic knee pain.

Intervention type: OTHER
Intervention: Healthy
Description: Healthy and non-symptomatic volunteers.
Study: NCT01345279

Intervention type: DRUG
Intervention: cisplatin
Description: 50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses

Intervention type: DRUG
Intervention: cisplatin
Description: 50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses

Intervention type: DRUG
Intervention: cisplatin
Description: 50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses

Intervention type: DRUG
Intervention: topotecan
Description: topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses

Intervention type: DRUG
Intervention: paclitaxel
Description: 135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
Study: NCT04249128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetarian Collagen
Description: Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetarian Collagen
Description: Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
Study: NCT06505473

Intervention type: BEHAVIORAL
Intervention: music-CBT
Description: notched relaxation music combined with personalized CBT
Study: NCT05469776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bicruciate-retaining total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior-stabilized total knee arthroplasty
Study: NCT04340570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication management via televisit to home
Description: Pharmacist led home based televisit for medication management
Study: NCT03365869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus or placebo were added to patients every day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus or placebo were added to patients every day
Study: NCT03657576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C134
Description: C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
Study: NCT03517657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilateral Motor Priming + Task Specific Training (BMP + TST)
Description: Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Priming + TST (CP + TST)
Description: The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
Study: NCT00608127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LupusorbTM
Description: Single treatment
Study: NCT04027634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin program
Description: This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
Study: NCT03814213

Intervention type: OTHER
Intervention: CGA
Description: Multi-level Health assessment

Intervention type: OTHER
Intervention: CGA
Description: Multi-level Health assessment

Intervention type: OTHER
Intervention: tailored care
Description: Tailored care based on problems identified by CGA
Study: NCT02459470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid loading
Description: fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
Study: NCT02195271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Study: NCT02431507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnap
Description: This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
Study: NCT02026401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02999646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVX-ONCO-1
Description: Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells
Study: NCT03788785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
Study: NCT02402608

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement
Description: oral essential amino acid (EAA), whey protein and vitamin D mixture

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
Study: NCT02088866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Lidocaine
Description: The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
Study: NCT02322866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarecycline
Description: 1.5 mg/kg/day taken orally at the same time each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching sarecycline tablets, taken orally at the same time each day.
Study: NCT03094923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days.
Study: NCT05110118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01008
Description: Single intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Single intravenous injection
Study: NCT02423746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up Behavioral Parenting Training Program (BPT)
Description: The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Placebo
Description: The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention.
Study: NCT04045054

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Link Team
Description: A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
Study: NCT01763125

Intervention type: OTHER
Intervention: Blood collection
Description: Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.

Intervention type: OTHER
Intervention: Blood collection
Description: Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.

Intervention type: OTHER
Intervention: Blood collection
Description: Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
Study: NCT04494191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin 100Mg Tab
Description: One tablet contains 100 mg Flibanserin
Study: NCT02756572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV
Study: NCT03380065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Late deflation of TR band
Description: 1. First 3ml of air is removed after TWO hour of sheath removal. Then, 3ml of air is removed every 15minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then a gap of 15minutes is observed for the next deflation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early deflation of TR band
Description: 1. First 2ml of air is removed from the band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 2ml of air should be pushed back into the device until bleeding stops. Then wait for another 30minutes for the next deflation.
Study: NCT01741987

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Optive ®
Description: instilation of 1 drop each eye 4 times per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Tears ®
Description: instilation of eye drop 4 times a day (qid)
Study: NCT03364101

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Composition of the placebo is 100% organic rice flour, manufactured at a facility New York State licensed to produce pharmaceuticals. Capsules will be instructed to commence on day 7 of the study after baseline appointment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: POWEROFF Capsule
Description: blend of California Poppy Aerial Part Extract, L-Cystine, L-Theanine,GABA (proprietary Phosphatidylcholine-Palmitic Acid-Oleic Acid Complex), 5-HTP, Magnolia Officinalis Bark Extract, Glycine, Melatonin with 0.5mg of Vitamin B6 (as pyridoxal-5-phosphate).
Study: NCT02330497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation under EUS
Description: Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
Study: NCT03732664

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab
Description: One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
Study: NCT01615458

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Care Model for Mood Disorders
Description: CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
Study: NCT04765930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Q-switched nd:YAG laser toning
Description: Q-switched nd:YAG laser toning for melasma.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Q-switched nd:YAG laser toning
Description: Q-switched nd:YAG laser toning for melasma.
Study: NCT00886080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using microwave energy
Description: The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.